Pluristem - Model PLX-Immune - Cells for Tumor Necrosis Factor Alpha (TNF-a) and Interferon-Gamma (IFN-g)

The product has been evaluated in pre-clinical studies and a peer-reviewed article in the journal Scientific Reports, from Nature, was published which examined the effect of the cells in over 50 lines of human cancerous cells. The results showed that PLX-Immune cells exhibited an anti-proliferative effect on 45 percent of the tested cancer cell lines, with a strong inhibitory effect on various lines of breast, colorectal, kidney, liver, lung, muscle and skin cancers. Comprehensive bioinformatics analysis identified common characteristics of the cancer cell lines inhibited by PLX cells. This knowledge could potentially be used in the future for screening patients’ tumors to identify those patients most likely to show a positive response to treatment with PLX cells.

An additional pre-clinical study of female mice harboring human triple negative breast cancer (TNBC) showed that weekly intramuscular (IM) injections of the cells produced a statistically significant reduction (p= 0.025) in mean tumor size in the treated group compared with the untreated group, with 30 percent of the treated mice exhibiting complete tumor remission. In addition, a statistically significant reduction (p=0.003) was seen in the percentage of proliferating tumor cells as well as in the level of blood vessels within the tumors.